1247 related articles for article (PubMed ID: 20505154)
1. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
2. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
Brignole C; Marimpietri D; Pastorino F; Nico B; Di Paolo D; Cioni M; Piccardi F; Cilli M; Pezzolo A; Corrias MV; Pistoia V; Ribatti D; Pagnan G; Ponzoni M
J Natl Cancer Inst; 2006 Aug; 98(16):1142-57. PubMed ID: 16912267
[TBL] [Abstract][Full Text] [Related]
3. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
4. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
[TBL] [Abstract][Full Text] [Related]
5. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
[TBL] [Abstract][Full Text] [Related]
6. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
[TBL] [Abstract][Full Text] [Related]
9. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
10. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
Qin JZ; Ziffra J; Stennett L; Bodner B; Bonish BK; Chaturvedi V; Bennett F; Pollock PM; Trent JM; Hendrix MJ; Rizzo P; Miele L; Nickoloff BJ
Cancer Res; 2005 Jul; 65(14):6282-93. PubMed ID: 16024630
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
14. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
LeBlanc R; Catley LP; Hideshima T; Lentzsch S; Mitsiades CS; Mitsiades N; Neuberg D; Goloubeva O; Pien CS; Adams J; Gupta D; Richardson PG; Munshi NC; Anderson KC
Cancer Res; 2002 Sep; 62(17):4996-5000. PubMed ID: 12208752
[TBL] [Abstract][Full Text] [Related]
16. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
Lü S; Yang J; Song X; Gong S; Zhou H; Guo L; Song N; Bao X; Chen P; Wang J
J Pharmacol Exp Ther; 2008 Aug; 326(2):423-31. PubMed ID: 18502982
[TBL] [Abstract][Full Text] [Related]
17. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
Fujita T; Doihara H; Washio K; Ino H; Murakami M; Naito M; Shimizu N
Anticancer Drugs; 2007 Jul; 18(6):677-86. PubMed ID: 17762396
[TBL] [Abstract][Full Text] [Related]
19. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Chauhan D; Catley L; Li G; Podar K; Hideshima T; Velankar M; Mitsiades C; Mitsiades N; Yasui H; Letai A; Ovaa H; Berkers C; Nicholson B; Chao TH; Neuteboom ST; Richardson P; Palladino MA; Anderson KC
Cancer Cell; 2005 Nov; 8(5):407-19. PubMed ID: 16286248
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
Satou Y; Nosaka K; Koya Y; Yasunaga JI; Toyokuni S; Matsuoka M
Leukemia; 2004 Aug; 18(8):1357-63. PubMed ID: 15190257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
